FLOW trial (revision 1)
Old revision·17:55, 25 Sep 2024·LurkerLevi
This is an old revision of this page, as it stood at 17:55, 25 Sep 2024, saved by LurkerLevi with the summary start article; endpoints and registration only. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| FLOW trial | |
|---|---|
| Drug | Semaglutide 1.0 mg weekly |
| Population | Type 2 diabetes with chronic kidney disease |
| Participants | 3,533 |
| Primary result | Kidney outcome HR 0.76 (95% CI 0.66–0.88) |
| Topic infobox · conventions | |
FLOW was a randomised, double-blind, placebo-controlled trial of weekly semaglutide 1.0 mg in 3,533 adults with type 2 diabetes and chronic kidney disease. It was stopped early for efficacy on the recommendation of its data monitoring committee.[1]
The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).[1]
References
Categories: